Login to Your Account



Tying Up Lucentis

Revisioning AMD: 'All Wet' Therapies Hung Out to Dry?

By Randy Osborne


Monday, May 3, 2010
Ophthotech Corp.'s kickoff last week of the Phase II trial with the aptamer E10030 as a combination therapy to be used with Lucentis drew still more attention to wet (neovascular) age-related macular degeneration, but quietly creeping up on the dreaded, more-common dry (atrophic) form of AMD is start-up ReVision Therapeutics Inc. with fenretinide, better known as a would-be cancer therapy.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription